Novo Nordisk and Eli Lilly cut obesity drug prices to compete in China
Novo Nordisk and Eli Lilly lowered prices of their leading obesity drugs Wegovy and Mounjaro in China to strengthen their positions in a rapidly expanding market facing rising obesity rates.
Comentarios
Publicar un comentario
Leave a comment. Thanks!
Comentarios de Facebook